Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.

Liposomes are used to efficiently deliver cargo molecules such as siRNA, mRNA, or RNA into cells in vitro and in vivo 3d rendered |Image Credit: © Love Employee - © Love Employee - stock.adobe.com

Nanoparticle Engineering in Drug Delivery Under the Microscope

By Feliza Mirasol

September 2nd 2023

Nanoparticles offer the potential for a safer, more effective method of drug delivery to the patient.

Takeda Gets Approval in Japan for Entyvio Subcutaneous Injection

By Feliza Mirasol

March 30th 2023

Takeda received approval in Japan for a subcutaneous injection formulation of Entyvio (vedolizumab) for treating ulcerative colitis.

Catalent Licenses Bhami Research Laboratory Technology for Biologics Formulation Development

By Feliza Mirasol

March 17th 2023

Under a technology licensing agreement with Bhami Research Laboratory, Catalent intends to develop formulations that will allow for the delivery of high-concentration biologics subcutaneously.

<1 2 3

About Us

Advertise

Editorial Information

Do Not Sell My Personal Information

Terms and Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777